Evidence map›Paper›PMID 32592708›Full record

ReviewNeuropharmacology2020

Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Asti Jackson, Ben Grobman, Suchitra Krishnan-Sarin

Open access · greenAbstract readReview
In one paragraph

Review in Neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Asti JacksonDepartment of Psychiatry, Yale School of Medicine, United States. Electronic address: asti.jackson@yale.edu.
Ben GrobmanDepartment of Psychiatry, Yale School of Medicine, United States.
Suchitra Krishnan-SarinDepartment of Psychiatry, Yale School of Medicine, United States.
Yale University · US

Funding

Yale Center for the Study of Tobacco Product Use and Addiction (YCSTP) Project 2: Addictive Threshold of Nicotine and the Impact of SweetenersU54DA036151 · NIDA · YALE UNIVERSITY · PI SUCHITRA KRISHNAN-SARIN · 2018 to 2026
$41.6M
Research Training Fellowship in Substance use and Addiction (RTFSA)T32DA007238 · NIDA · YALE UNIVERSITY · PI BRIAN D. KILUK, ISMENE L. PETRAKIS · 1988 to 2026
$5.7M
Mentoring Emerging Scientists for Careers in Substance Use ResearchR25DA035163 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carmen L Masson, Gideon St.Helen · 2014 to 2026
$4.6M
NIDA NIH HHS R25 DA035163NIDA NIH HHS T32 DA007238NIDA NIH HHS U54 DA036151
6 · The paper itself

Abstract

introductionThe rise of vaping in adolescents, the recent entrance of new inhaled nicotine products such as iQOS on the market and e-cigarette or vaping product use-associated lung injury cases has created concern for the use of inhaled non-combustible nicotine products. This narrative review discusses recent experimental in vivo studies that utilize human, rat and mouse models to understand the pharmacological impact of nicotine from non-combustible products.

methodsThe search engine PubMed was utilized with the following search terms: inhaled nicotine, nicotine e-cigarette, heated tobacco products, iQOS, electronic cigarette, nicotine inhaler, nicotine vaping. This review highlights recent primary in vivo studies of inhaled nicotine administration experimental paradigms that occurred in laboratory settings using human and rodent (rats and mice) models that have been published from January 2017-December 2019.

resultsThe pharmacokinetics of nicotine via e-cigarettes is influenced by the PG/VG and flavor constituents in e-liquids, the presence of nicotine salts in e-liquids, puff topography of nicotine and tobacco product users and the power of the e-cigarette device. The pharmacodynamic impact of inhaled nicotine has cardiovascular, pulmonary and central nervous system implications.

conclusionThe articles reviewed here highlight the importance of both animal and human models to fully understand the impact of inhaled nicotine pharmacology There is a need for more rodent pharmacokinetic inhaled nicotine studies to understand the influences of factors such as flavor and nicotine salts. Additionally, consensus on nicotine measurement in both human and rodent studies is greatly needed.

Indexed as

Electronic Nicotine Delivery SystemsAdministration, InhalationAnimalsClinical Trials as TopicDrug Evaluation, PreclinicalHumansNicotineTobacco Use DisorderVapingNicotine

Identifiers

PMID32592708
PMCPMC7529934
OpenAlexW3037367917

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.